Preclinical Evidence of Alzheimer Changes: Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings

BACKGROUND: Alterations in cerebrospinal fluid (CSF) tau and β–amyloid peptide 1–42 (Aβ(42)) levels and rates of cerebral glucose (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG PET) occur years before clinical symptoms of Alzheimer’s disease (AD) become manifest, but their relation...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Petrie, Eric C., Cross, Donna J., Galasko, Douglas, Schellenberg, Gerard D., Raskind, Murray A., Peskind, Elaine R., Minoshima, Satoshi
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2718788/
https://ncbi.nlm.nih.gov/pubmed/19433663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2009.59
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars